Enzo Biochem, Inc. (ENZB) Stock

About Enzo Biochem, Inc.

Enzo Biochem, Inc. operates as an integrated entity encompassing diagnostics, clinical laboratory services, and life sciences. The company is dedicated to developing, manufacturing, and commercializing diagnostic and research products, fundamentally rooted in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division focuses on creating, producing, and distributing essential products and tools for clients engaged in clinical research, pharmaceutical development, and broader bioscience investigations. Its extensive portfolio comprises proteins, antibodies, peptides, small molecules, labeling probes, dyes, and various kits. These offerings empower life science researchers in areas such as target identification and validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also serves scientific experts researching a wide array of health issues, including cancer, cardiovascular disorders, neurological diseases, diabetes and obesity, endocrine imbalances, infectious and autoimmune conditions, hepatotoxicity, and renal injury. Through its Clinical Laboratory Services segment, Enzo Biochem provides a spectrum of molecular and other clinical laboratory tests and procedures. These are utilized in routine patient care by medical professionals to aid in establishing or corroborating diagnoses, monitoring treatment efficacy or medication levels, and uncovering previously undiagnosed conditions. This segment operates a full-scale clinical laboratory in Farmingdale, New York, supported by a network of 30 patient service centers throughout New York and New Jersey. Furthermore, it manages specialized "STAT" or rapid response laboratories in New York City and Connecticut, along with a complete phlebotomy center and an internal logistics department. The Therapeutics segment is committed to devising innovative solutions for gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem promotes its products and services globally through a dedicated direct sales force and an established network of distributors. The company was founded in 1976 and maintains its corporate headquarters in New York, New York.

Enzo Biochem, Inc. is headquartered in US.

Enzo Biochem, Inc. (ENZB) stock trades at $0.70 with a market capitalization of $36.59M. The stock is valued at a price-to-earnings (P/E) ratio of -8.80, price-to-book of 0.84, price-to-sales of 2.66. Over the past 52 weeks the stock has ranged between $0.25 and $1.19, and currently trades 41.2% below its 52-week high.

On profitability, Enzo Biochem, Inc. generates a return on equity (ROE) of -9.61%, return on capital employed of -10.73%, an operating margin of -36.34%, a net profit margin of -31.49%.

Official website: www.enzo.com